SBI Securities Co. Ltd. Invests $28,000 in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

SBI Securities Co. Ltd. acquired a new position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 27,856 shares of the biopharmaceutical company’s stock, valued at approximately $28,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Golden State Equity Partners boosted its stake in Sangamo Therapeutics by 2,592.3% in the 4th quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company’s stock worth $332,000 after purchasing an additional 313,587 shares in the last quarter. Geode Capital Management LLC boosted its stake in Sangamo Therapeutics by 14.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after purchasing an additional 272,123 shares in the last quarter. Virtu Financial LLC acquired a new stake in Sangamo Therapeutics in the 3rd quarter worth approximately $150,000. State Street Corp boosted its stake in Sangamo Therapeutics by 28.0% in the 3rd quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company’s stock worth $576,000 after purchasing an additional 145,400 shares in the last quarter. Finally, FMR LLC lifted its stake in Sangamo Therapeutics by 16.5% during the 3rd quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company’s stock valued at $471,000 after acquiring an additional 77,032 shares during the period. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Wall Street Analyst Weigh In

SGMO has been the subject of several research reports. Jefferies Financial Group decreased their price objective on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, December 31st. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research note on Monday, January 27th. Barclays boosted their target price on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Truist Financial decreased their target price on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Finally, StockNews.com cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $5.17.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ SGMO opened at $1.00 on Thursday. The firm has a market cap of $207.88 million, a PE ratio of -1.33 and a beta of 1.49. The firm has a fifty day moving average of $1.12 and a 200 day moving average of $1.40. Sangamo Therapeutics, Inc. has a one year low of $0.30 and a one year high of $3.18.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.